md-medicaldata

Authors

Dina Stojanović², Viktorija Dragojević Simić^1,2, Nemanja Rančić<sup>1,2

1</sup>Centre for Clinical Pharmacology, Military Medical Academy, Belgrade, Serbia
²Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia

 

UDK: 616-006.5-03

The paper was received / Rad primljen 18.04.2025.

Accepted / Rad prihvaćen: 21.04.2025.

 

Correspondence to:

Nemanja Rančić
Vojnomedicinska akademija Beograd
Tel: 063-8524443
e-mail: nece84@hotmail.com

 

 

Sažetak

 

 

Razvoj inovativnih terapijskih strategija u onkologiji postaje imperativ zbog sve učestalije rezistencije tumorskih ćelija na konvencionalne terapije. Fitohemikalije, odnosno hemijska jedinjenja ili supstance poreklom iz biljaka i farmakološki agensi sa antitumorskim potencijalom postaju sve značajniji subjekti istraživanja. Ovaj rad daje pregled ključnih jedinjenja, uključujući resveratrol, genistein, kurkumin, fisetin, biohanin A, tetrandrin i metformin uključujući njihove potencijalne molekularne mehanizme delovanja u inhibiciji tumorskog rasta. Poseban fokus stavljen je na procese inhibicije proliferacije, indukcije apoptoze, modulacije ćelijskog ciklusa, angiogeneze i metastaziranja. U radu su detaljno razmatrani mehanizmi putem kojih ova jedinjenja ostvaruju antitumorske efekte, uključujući interakcije sa ključnim signalnim putevima kao što su PI3K/Akt/mTOR, NF-κB, JAK/STAT i MAPK. Razumevanje ovih mehanizama može doprineti razvoju novih terapijskih strategija koje bi bile efikasnije i sa manje neželjenih efekata u odnosu na standardne terapije.

 

Ključne reči:

razvoj lekova, antitumorska terapija, mehanizmi delovanja, fitohemikalije, signalni putevi tumorskih ćelija

 

 

 

Abstract

 

The development of innovative therapeutic strategies in oncology is becoming imperative due to the increasing resistance of tumor cells to conventional therapies. Phytochemicals, i.e., chemical compounds or substances of plant origin and pharmacological agents with antitumor potential, are becoming increasingly essential research subjects. This paper provides an overview of key compounds, including resveratrol, genistein, curcumin, fisetin, biochanin A, tetrandrin and metformin, and their potential molecular mechanisms of action inhibiting tumor growth. Special focus is placed on the processes of inhibition of proliferation, apoptosis induction, cell cycle modulation, angiogenesis and metastasis. The paper discusses how these compounds exert antitumor effects, including interactions with key signaling pathways such as PI3K/Akt/mTOR, NF-κB, JAK/STAT and MAPK. Understanding these mechanisms may contribute to developing more effective therapeutic strategies with fewer side effects compared to standard therapies.

 

Key words:

drug development, antitumor therapy, mechanisms of action, phytochemicals, signaling pathways of tumor cells

 

 

 

 

References:

1. World Health Organization. Cancer. 2025. Dostupno na: https://www.who.int/news-room/fact-sheets/detail/cancer
2. International Agency for Research on Cancer- World Health Organization: Global Cancer Observatory. Cancer Today: Estimated number of new cases in 2023, worldwide. 2025. Dostupno na: https://gco.iarc.fr/today/home
3. Almilaibary A. Phyto-therapeutics as anti-cancer agents in breast cancer: Pathway targeting and mechanistic elucidation. Saudi J Biol Sci. 2024;31(3):103935. doi: 10.1016/j.sjbs.2024.103935.
4. Chen T, Wang J, Li M, Wu Q, Cui S. Genistein Inhibits Proliferation and Metastasis in Human Cervical Cancer Cells through the Focal Adhesion Kinase Signaling Pathway: A Network Pharmacology-Based In Vitro Study in HeLa Cells. Molecules. 2023;28(4):1919. doi: 10.3390/molecules28041919.
5. Ge W, Yuan G, Wang D, Dong L. Exploring the therapeutic mechanisms and prognostic targets of Biochanin A in glioblastoma via integrated computational analysis and in vitro experiments. Sci Rep. 2024;14(1):3783. doi: 10.1038/s41598-024-53442-0.
6. Li J, Kou Y, Zhang X, Xiao X, Ou Y, Cao L, Guo M, Qi C, Wang Z, Liu Y, Shuai Q, Wang H, Yang S. Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1. Discov Oncol. 2022;13(1):138. doi: 10.1007/s12672-022-00601-2.
7. Xu J, Yang X, Pan J, Fan H, Mei J, Hua D. Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer. J Oncol. 2022;2022:3224373. doi: 10.1155/2022/3224373.
8. Dixon RA, Ferreira D. Genistein. Phytochemistry. 2002;60(3):205-11. doi: 10.1016/s0031-9422(02)00116-4.
9. Yang D, Zhang Q, Kuang H, Liu J, Wu S, Wei L, Yao W. The antitumor activity of tangeretin in esophageal squamous cell carcinoma by inhibiting GLI2-mediated transcription of GPNMB. PLoS One. 2024;19(6):e0291531. doi: 10.1371/journal.pone.0291531.
10. Xu H, Ma H, Zha L, Li Q, Pan H, Zhang L. Genistein promotes apoptosis of lung cancer cells through the IMPDH2/AKT1 pathway. Am J Transl Res. 2022;14(10):7040-7051.
11. Kim SH, Kim SH, Kim YB, Jeon YT, Lee SC, Song YS. Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells. Ann N Y Acad Sci. 2009;1171:495-500. doi: 10.1111/j.1749-6632.2009.04899.x.
12. Wu Q, Wu W, Jacevic V, Franca TCC, Wang X, Kuca K. Selective inhibitors for JNK signalling: a potential targeted therapy in cancer. J Enzyme Inhib Med Chem. 2020;35(1):574-583. doi: 10.1080/14756366.2020.1720013.
13. Zhou Y, Mu L, Liu XL, Li Q, Ding LX, Chen HC, Hu Y, Li FS, Sun WJ, He BC, Wu K. Tetrandrine inhibits proliferation of colon cancer cells by BMP9/ PTEN/ PI3K/AKT signaling. Genes Dis. 2019;8(3):373-383. doi: 10.1016/j.gendis.2019.10.017.
14. Tan Y, Zhu Q, Yang M, Yang F, Zeng Q, Jiang Z, Li D. Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer. Pharmacol Res. 2024;207:107314. doi: 10.1016/j.phrs.2024.107314.
15. Wang Y, Xu T, Wang H, Xia G, Huang X. Inhibition of autophagy induced by tetrandrine promotes the accumulation of reactive oxygen species and sensitizes efficacy of tetrandrine in pancreatic cancer. Cancer Cell Int. 2024;24(1):241. doi: 10.1186/s12935-024-03410-5.
16. Wang CH, Yang JM, Guo YB, Shen J, Pei XH. Anticancer Activity of Tetrandrine by Inducing Apoptosis in Human Breast Cancer Cell Line MDA-MB-231 In Vivo. Evid Based Complement Alternat Med. 2020;2020:6823520. doi: 10.1155/2020/6823520.
17. Liu Y, Cao H, Zhao Y, Shan L, Lan S. Fisetin-induced cell death in human ovarian cancer cell lines via zbp1-mediated necroptosis. J Ovarian Res. 2022;15(1):57. doi: 10.1186/s13048-022-00984-4.
18. Kim TW. Fisetin, an Anti-Inflammatory Agent, Overcomes Radioresistance by Activating the PERK-ATF4-CHOP Axis in Liver Cancer. Int J Mol Sci. 2023;24(10):9076. doi: 10.3390/ijms24109076.
19. Afroze N, Pramodh S, Shafarin J, Bajbouj K, Hamad M, Sundaram MK, Haque S, Hussain A. Fisetin Deters Cell Proliferation, Induces Apoptosis, Alleviates Oxidative Stress and Inflammation in Human Cancer Cells, HeLa. Int J Mol Sci. 2022;23(3):1707. doi: 10.3390/ijms23031707.
20. Kubina R, Krzykawski K, Dziedzic A, Kabała-Dzik A. Kaempferol and Fisetin-Related Signaling Pathways Induce Apoptosis in Head and Neck Cancer Cells. Cells. 2023;12(12):1568. doi: 10.3390/cells12121568.
21. Liu C, Rokavec M, Huang Z, Hermeking H. Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis. Cell Death Differ. 2023;30(7):1771-1785. doi: 10.1038/s41418-023-01178-1.
22. Tang X, Ding H, Liang M, Chen X, Yan Y, Wan N, Chen Q, Zhang J, Cao J. Curcumin induces ferroptosis in non-small-cell lung cancer via activating autophagy. Thorac Cancer. 2021;12(8):1219-1230. doi: 10.1111/1759-7714.13904. Erratum in: Thorac Cancer. 2024;15(14):1197. doi: 10.1111/1759-7714.15298.
23. Cao X, Li Y, Wang Y, Yu T, Zhu C, Zhang X, Guan J. Curcumin suppresses tumorigenesis by ferroptosis in breast cancer. PLoS One. 2022;17(1):e0261370. doi: 10.1371/journal.pone.0261370.
24. de Luna FCF, Ferreira WAS, Casseb SMM, de Oliveira EHC. Anticancer Potential of Flavonoids: An Overview with an Emphasis on Tangeretin. Pharmaceuticals (Basel). 2023;16(9):1229. doi: 10.3390/ph16091229.
25. Gv V, Ranganathan P Jr, Palati S. Tangeretin's Anti-apoptotic Signaling Mechanisms in Oral Cancer Cells: In Vitro Anti-cancer Activity. Cureus. 2023;15(10):e47452. doi: 10.7759/cureus.47452.
26. Ko YC, Choi HS, Liu R, Kim JH, Kim SL, Yun BS, Lee DS. Inhibitory Effects of Tangeretin, A Citrus Peel-Derived Flavonoid, on Breast Cancer Stem Cell Formation through Suppression of Stat3 Signaling. Molecules. 2020;25(11):2599. doi: 10.3390/molecules25112599.
27. Zhang N, Wu W, Huang Y, An L, He Z, Chang Z, He Z, Lai Y. Citrus Flavone Tangeretin Inhibits CRPC Cell Proliferation by Regulating Cx26, AKT, and AR Signaling. Evid Based Complement Alternat Med. 2022;2022:6422500. doi: 10.1155/2022/6422500.
28. Yang Z, Zhou Z, Meng Q, Chen Z, Yun L, Jiang J, He Y, Dian M, Zhang R, Ge H, Yan T, Men B, Li Z, Wu X, He J, Rao S. Dihydroartemisinin Sensitizes Lung Cancer Cells to Cisplatin Treatment by Upregulating ZIP14 Expression and Inducing Ferroptosis. Cancer Med. 2024;13(19):e70271. doi: 10.1002/cam4.70271.
29. Yang J, Zhou Y, Xie S, Wang J, Li Z, Chen L, Mao M, Chen C, Huang A, Chen Y, Zhang X, Khan NUH, Wang L, Zhou J. Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. J Exp Clin Cancer Res. 2021;40(1):206. doi: 10.1186/s13046-021-02012-7.
30. Finisguerra V, Dvorakova T, Formenti M, Van Meerbeeck P, Mignion L, Gallez B, Van den Eynde BJ. Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. J Immunother Cancer. 2023;11(5):e005719. doi: 10.1136/jitc-2022-005719.
31. Ye J, Cai S, Feng Y, Li J, Cai Z, Deng Y, Liu R, Zhu X, Lu J, Zhuo Y, Liang Y, Xie J, Zhang Y, He H, Han Z, Jia Z, Zhong W. Metformin escape in prostate cancer by activating the PTGR1 transcriptional program through a novel super-enhancer. Signal Transduct Target Ther. 2023;8(1):303. doi: 10.1038/s41392-023-01516-2.
32. Deng C, Xiong L, Chen Y, Wu K, Wu J. Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer. BMC Pulm Med. 2023;23(1):360. doi: 10.1186/s12890-023-02655-6.
33. Bai B, Wu F, Ying K, Xu Y, Shan L, Lv Y, Gao X, Xu D, Lu J, Xie B. Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer. Theranostics. 2021;11(13):6225-6239. doi: 10.7150/thno.55939.
34. Zheng J, Li X, Yang W, Zhang F. Dihydroartemisinin regulates apoptosis, migration, and invasion of ovarian cancer cells via mediating RECK. J Pharmacol Sci. 2021;146(2):71-81. doi: 10.1016/j.jphs.2021.02.001.
35. Yan Y, Yang X, Han N, Liu Y, Liang Q, Li LG, Hu J, Li TF, Xu Z. Metal-organic framework-encapsulated dihydroartemisinin nanoparticles induces apoptotic cell death in ovarian cancer by blocking ROMO1-mediated ROS production. J Nanobiotechnology. 2023;21(1):204. doi: 10.1186/s12951-023-01959-3.
36. Rojo D, Madrid A, Martín SS, Párraga M, Silva Pinhal MA, Villena J, Valenzuela-Valderrama M. Resveratrol Decreases the Invasion Potential of Gastric Cancer Cells. Molecules. 2022;27(10):3047. doi: 10.3390/molecules27103047.
37. Fukuda M, Ogasawara Y, Hayashi H, Inoue K, Sakashita H. Resveratrol Inhibits Proliferation and Induces Autophagy by Blocking SREBP1 Expression in Oral Cancer Cells. Molecules. 2022;27(23):8250. doi: 10.3390/molecules27238250.
38. Jiang H, Wang GT, Wang Z, Ma QY, Ma ZH. Resveratrol inhibits pancreatic cancer proliferation and metastasis by depleting senescent tumor-associated fibroblasts. World J Gastrointest Oncol. 2024;16(9):3980-3993. doi: 10.4251/wjgo.v16.i9.3980.
39. Pintova S, Dharmupari S, Moshier E, Zubizarreta N, Ang C, Holcombe RF. Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. Cancer Chemother Pharmacol. 2019;84(3):591-598. doi: 10.1007/s00280-019-03886-3.
40. Brown JR, Chan DK, Shank JJ, Griffith KA, Fan H, Szulawski R, Yang K, Reynolds RK, Johnston C, McLean K, Uppal S, Liu JR, Cabrera L, Taylor SE, Orr BC, Modugno F, Mehta P, Bregenzer M, Mehta G, Shen H, Coffman LG, Buckanovich RJ. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020;5(11):e133247. doi: 10.1172/jci.insight.133247.
41. Akce M, Farran B, Switchenko JM, Rupji M, Kang S, Khalil L, Ruggieri-Joyce A, Olson B, Shaib WL, Wu C, Alese OB, Diab M, Lesinski GB, El-Rayes BF. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer. J Immunother Cancer. 2023;11(10):e007235. doi: 10.1136/jitc-2023-007235.
42. Panknin TM, Howe CL, Hauer M, Bucchireddigari B, Rossi AM, Funk JL. Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials. Int J Mol Sci. 2023;24(5):4476. doi: 10.3390/ijms24054476.
43. Cikota-Aleksić B, Rančić N, Ratković N, Dragojević-Simić V. The basic principals of pharmacogenetics testing in cancer treatment. Hospital Pharmacology - International Multidisciplinary Journal. 2020;7(1):895-902. doi: 10.5937/hpimj2001895C.
    

PDF: 07-Stojanović D. et al MD-Medical Data 2025;17(2) 123-129.pdf